Discuss innovative applications and recent technological developments within the fields of multiplexed assays and flow cytometry
The programme brings together world leaders from international pharmaceutical organisations and leading biotechnology companies to discuss the latest in multi-omic cytometry and its application in immuno-oncology and infectious diseases alongside advances in multiplexing tools for biomarker analysis.
Full details on the Symposium including the presentations, topic areas and confirmed speakers will be released in the conference brochure in the coming weeks
Registration for Virtual Symposium: Flow Cytometry & Multiplexing Tools is now open. Please click the button below to register for this event.
Our LinkedIn group aims to foster discussion and collaboration between experts interested in the latest biomarker strategies and technologies
Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions working within multi-omic cytometry and its application in immuno-oncology and infectious diseases
Stream 1: Latest Strategies And Technologies Progressing Flow Cytometry
Stream Two: Multiplexing Tools & Technologies For Biomarker Analysis
The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future
Previous speakers at 2020’s Biomarkers Series UK included:
Nottingham Trent University
F. Hoffman-La Roche Ltd.
Networking and knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer flexible solutions for hospitals, reference labs, and researchers, as well as innovative xMAP® and flow cytometry solutions that span a wide variety of applications, including molecular diagnostics, drug discovery, life science research, immunology, and personalized medicine. For further information, please visit luminexcorp.com.
Eurofins Discovery supports Drug Discovery through the combined expertise of Cerep, DiscoverX, Panlabs, Villapharma, and Selcia Drug Discovery. We offer a broad portfolio including medicinal and synthetic chemistry, in vitro pharmacology products and services, cell-based phenotypic assays, ADME-Tox, in vivo drug safety and efficacy, custom proteins, and assay development services. Eurofins Discovery provides the experience, depth, breadth, and innovative testing services and product tools to support researchers in their endeavors to accelerate the discovery and development of candidate molecules.
Eurofins DiscoverX, the Eurofins Discovery products company, is the trusted products solutions provider enabling scientists from drug discovery to post-market validation. Offering the most comprehensive portfolio of biologically-relevant and qualified cell-based assays, stable cell lines, and optimized reagents across the major therapeutic targets, confidently accelerate your biologics and small molecule drug discovery programs today.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.